Follow
About Sel
Sel Hardy joined CFRA in October 2019 and is a fundamental equity research analyst covering several segments within the healthcare sector such as pharmaceuticals, managed health care, life sciences tools and services, health care distributors, and services. Prior to joining CFRA, she worked in equity and fixed-income research at Is Investment, the leading investment bank in Turkey. Ms. Hardy analyzed stocks and corporate bonds traded on the Istanbul Stock Exchange.
Sel's Articles
The Focus Stock of the Week ended September 10 is Eli Lilly and Company (LLY), which carries CFRA's highest investment recommendation of 5-STARS, or Strong Buy. We see several catalysts that make us bullish on shares of LLY in the medium to long term, notes Sel Hardy, analyst at CFRA Research.
As one of the world's largest biopharmaceutical companies, we think Pfizer (PFE) is well-positioned to outperform its peers; the stock carries our highest recommendation of 5-STARS, or Strong Buy, asserts analyst Sel Hardy in CFRA Research's flagship newsletter, The Outlook.
Centene Corporation (CNC) carries CFRA's highest investment recommendation of 5-STARS, or Strong Buy, notes analyst Sel Hardy in CFRA Research's flagship newsletter, The Outlook.
Zoetis (ZTS) is among the top global companies in the discovery, development, manufacture, and marketing of animal health medicines and vaccines, with a focus on both livestock and companion animals, explains equity analyst Sel Hardy in CFRA Research's The Outlook.